Get the Stockscreener App
1,021.41
3.37%
33.32
After Hours:
1018.09
-3.32
-0.33%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,021.41, with a volume of 3.72M.
It is up +3.37% in the last 24 hours and up +10.18% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$988.09
Open:
$989.51
24h Volume:
3.72M
Relative Volume:
1.22
Market Cap:
$910.83B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
36.77
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+3.19%
1M Performance:
+10.18%
6M Performance:
-2.69%
1Y Performance:
+35.27%
1-Day Range:
$984.60
$1,021.80
1-Week Range:
$978.87
$1,022.82
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,021.41 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.00 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.76 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.44 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
184.64 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Co (LLY) Shares Surge 3.4% -- What GF Score of 98 Tells Investors - GuruFocus
Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm - The Guardian
Eli Lilly stock (US5324571083): blockbuster obesity drugs keep growth story in focus - AD HOC NEWS
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report - Benzinga
President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill - TipRanks
A new ranking of pharma companies by R&D performance - statnews.com
Trump bought stock in drugmaker as his government boosted its obesity drugs - Fierce Pharma
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Eli Lilly tops prominent rankings on pharma R&D performance - statnews.com
Eli Lilly stock (US5324571083): weight-loss boom drives Q1 2026 earnings jump - AD HOC NEWS
Eli Lilly Is A Buy (Technical Analysis) - Seeking Alpha
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Motley Fool
Eli Lilly Stock: Next Stop $2,000? - AOL.com
Eli Lilly Stock: Next Stop $2,000? - The Motley Fool
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly (LLY) Supreme Court Challenge Dismissed, $183 Million Judgment Stands - GuruFocus
US Supreme Court turns away Eli Lilly’s challenge to whistleblower law - The Journal Record
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud CaseEli Lilly (NYSE:LLY) - Benzinga
Justices Deny Eli Lilly's Qui Tam Constitutional Challenge - Law360
Lilly rebuffed by Supreme Court on $194M Medicaid award - The Indiana Lawyer
Eli Lilly to Attend Bernstein Annual Strategic Decision Conferen - GuruFocus
Eli Lilly (LLY) Supreme Court Ruling Leaves Lower Court Decision Intact - GuruFocus
Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals - Moomoo
Supreme Court rejects Eli Lilly challenge to Civil War era law on Medicaid fraud - The Independent
Eli Lilly (LLY) Dealt Blow as U.S. Supreme Court Refuses to Hear Whistleblower Law Challenge - TipRanks
US Supreme Court turns away Eli Lilly's challenge to whistleblower law - Reuters
US Supreme Court turns away Eli Lilly’s challenge to whistleblower law By Reuters - Investing.com
Eli Lilly loses Supreme Court appeal of $194 million fraud award - Investing.com Canada
Lilly's Daniel Skovronsky joins Bernstein fireside chat on May 28 - Stock Titan
Lilly Rebuffed by Supreme Court on $194 Million Medicaid Award - Bloomberg.com
Trump bought stock in drugmaker Eli Lilly as his government boosted its obesity drugs - Tucson Sentinel
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says - Proactive Investors
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet - European Biotechnology Magazine
LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuation - ChartMill
Eli Lilly & Co stock (US5324571083): Q1 2026 earnings beat underscores obesity and diabetes momentum - AD HOC NEWS
Eli Lilly and Company $LLY Shares Acquired by Sapient Capital LLC - MarketBeat
North Dakota State Investment Board Purchases Shares of 27,482 Eli Lilly and Company $LLY - MarketBeat
Passumpsic Savings Bank Takes Position in Eli Lilly and Company $LLY - MarketBeat
RiverFront Investment Group LLC Has $31.28 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
GLOBALT Investments LLC GA Buys 1,760 Shares of Eli Lilly and Company $LLY - MarketBeat
3,516 Shares in Eli Lilly and Company $LLY Purchased by Aegis Wealth Management Inc. - MarketBeat
Eli Lilly & Co stock (US5324571083): Q1 2026 earnings surge and obesity boom keep rally in focus - AD HOC NEWS
Mounjaro demand keeps Eli Lilly in the spotlight in the US - AD HOC NEWS
Eli Lilly and Co stock (US5324571083): rally fueled by weight-loss boom and fresh earnings momentum - AD HOC NEWS
Two Stocks to Sell and One to Buy: Wall Street's 20%+ Price Target Picks | May 2026News and Statistics - IndexBox
Eli Lilly Expands Indiana Manufacturing With New 4.5 Billion Investment - AsatuNews.co.id
Eli Lilly and Co. | Pharmaceuticals, Biomedical Research, & Company - Britannica
Pharma Earnings Season 2026: Amphastar Flat, Eli Lilly Surges in Q1News and Statistics - IndexBox
$LLY Stock Rose 5% This Week. Here's What We See in Our Data. - Moomoo
Eli Lilly Stock Rises 2.4% on $4.5B Manufacturing Investment and Strong Demand - IndexBox
Caitlin Clark Foundation & Eli Lilly launch three Indy community courts - WISH-TV
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):